FDA reforms could boost U.S. economy; Novartis arthritis drug gains EU approval;

@FiercePharma: Merck's Tredaptive fiasco blamed on adverse reactions to niacin. Article | Follow @FiercePharma

@EricPFierce: Must be some folks sorry Mylan got Agila and they didn't. Hikma says it is getting interest in its injectables biz. Story | Follow @EricPFierce

> Anacor Pharmaceuticals ($ANAC) received upbeat results from the second of two Phase III trials of tavaborole, a topical anti-fungal for the treatment of onychomycosis, a common fungal nail infection in the U.S. Release

> The FDA has granted fast-track status for Cubist Pharmaceuticals' ($CBST) antibiotic ceftolozane/tazobactam to treat bacterial pneumonia and complicated urinary tract infections as well as ceftolozane/tazobactam and surotomycin for complicated intra-abdominal infections (cIAI) and Clostridium difficile-associated diarrhea, respectively. Release

> Novartis' ($NVS) drug Ilaris has been approved in Europe for patients with gout, an often painful type of inflammatory arthritis. Item

> Streamlining FDA processes and cutting inefficiencies could boost U.S. economy. Story

Biotech News

 @FierceBiotech: From FierceBiotechIT.com : GSK jumps new IT hurdles in 'real-world' test of blockbuster hopeful. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Lundbeck gets EU nod for new drug to fight alcohol addiction--$300M tops; no U.S. plans. Story | Follow @JohnCFierce

@RyanMFierce: Alere grabbed some Gates Foundation funding for Tuberculosis and HIV testing products. Release | Follow @RyanMFierce

> As sequestration dawns, FDA supporters scramble to ease woes on drug reviews. Report

> Facebook, Google geeks 'hack' into cancer research problem with mobile game. More

> FDA pins approval on once-monthly version of blockbuster Abilify. Article

Medical Device News

 @FierceMedDev: Boston Scientific posts positive Watchman data. Item | Follow @FierceMedDev

 @MarkHFierce: Fledgling Dx company GeneCentric is raising money to support a lung cancer Dx commercial launch. More | Follow @MarkHFierce

 @DamianFierce: More worry for Intuitive Surgical as the FDA gets involved in the scrutiny of da Vinci robots. Story | Follow @DamianFierce

> Wright finalizes $190M-plus buy of BioMimetic. Story

> AtriCure 2012 losses, revenue grew as market push unfolded. Article

> Alere snags up to $42.2M from Gates Foundation for TB Dx. News

And Finally... EntreMed is raising $10.7 million of securities in a registered direct offering. Release

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.